title: Relationship between Blood Pressure and Outcomes in Acute Ischemic Stroke Patients Administered Lytic Medication in the TIMS-China Study.
abstract: OBJECTIVE
  Increased blood pressure (BP) management following acute ischemic stroke (AIS) remains controversial. This study aimed to identify the association between BP and clinical outcomes in AIS patients administered lytic medication in the TIMS-China (thrombolysis implementation and monitor of acute ischemic stroke in China) database.
  
  
  METHODS
  The sample comprised 1128 patients hospitalized within 4.5 hours (h) of AIS for intravenous recombinant tissue plasminogen activator (i.v. rt-PA) thrombolysis. Systolic BP (SBP) and diastolic BP (DBP) at baseline, 2 h and 24 h after treatment, and changes from baseline were analyzed. The study outcomes comprised a favorable outcome (modified Rankin Scale 0-1 at 90 days) and symptomatic intracerebral hemorrhage (SICH), analyzed using logistic regression, with low BP as the reference group.
  
  
  RESULTS
  Lower BP (baseline, 2 h, and 24 h) was beneficial in AIS patients and significantly related to a favorable outcome (P<0.05). A substantial BP decrease at 24 h after rt-PA thrombolysis was significantly associated with a favorable outcome compared with a moderate BP decrease (P = 0.0298). A SBP >160 mmHg 2 h after rt-PA thrombolysis was significantly associated with SICH compared with a SBP <140 mmHg (P = 0.0238). An increase or no change (>25 mmHg) in SBP was significantly associated with SICH (P = 0.002) compared with a small SBP decrease (1-9 mmHg).
  
  
  CONCLUSIONS
  This study provides novel evidence that lower BP within the first 24 h is associated with a more favorable outcome and less frequent SICH in AIS patients administered lytic medication. Routine BP-lowering treatment should be considered in AIS patients following lytic medication.
authors.affiliation: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.|Department of neurology, Qilu Hospital of Shandong University, Jinan China & Braian Science Research Institute, Shandong University, Jinan, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wu
authors.affiliation: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
authors.forename: Xiaochuan
authors.initials: X
authors.lastname: Huo
authors.affiliation: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
authors.forename: Xingquan
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Liao
authors.affiliation: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
authors.forename: Chunjuan
authors.initials: C
authors.lastname: Wang
authors.affiliation: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
authors.forename: Yuesong
authors.initials: Y
authors.lastname: Pan
authors.affiliation: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
authors.forename: Yilong
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
authors.forename: Yongjun
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000368:Aged; D001794:Blood Pressure; D002545:Brain Ischemia / Q000150:complications / Q000503:physiopathology* / Q000628:therapy*; D002681:China; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000150:complications / Q000503:physiopathology* / Q000628:therapy*; D013599:Systole; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010959:Tissue Plasminogen Activator
references.citation: Cochrane Database Syst Rev. 2014;(7):CD000213
references.pmid: 25072528
references.citation: Stroke. 2002 May;33(5):1315-20
references.pmid: 11988609
references.citation: Can J Cardiol. 2015 May;31(5):549-68
references.pmid: 25936483
references.citation: Stroke. 2015 Oct;46(10):3020-35
references.pmid: 26123479
references.citation: Acta Neurol Scand. 2002 Sep;106(3):142-7
references.pmid: 12174173
references.citation: Stroke. 2003 Oct;34(10):2420-5
references.pmid: 14500934
references.citation: J Intern Med. 2004 Feb;255(2):257-65
references.pmid: 14746563
references.citation: Stroke. 1986 Sep-Oct;17(5):861-4
references.pmid: 3764955
references.citation: Neurology. 2005 Oct 25;65(8):1179-83
references.pmid: 16247043
references.citation: J Hypertens. 2007 Jan;25(1):73-9
references.pmid: 17143176
references.citation: Am J Emerg Med. 2007 Jan;25(1):32-8
references.pmid: 17157679
references.citation: Stroke. 2008 Feb;39(2):366-72
references.pmid: 18096843
references.citation: Cerebrovasc Dis. 2008;25(3):202-8
references.pmid: 18212508
references.citation: Stroke. 2009 Jun;40(6):2098-103
references.pmid: 19359649
references.citation: Stroke. 2009 Jul;40(7):2442-9
references.pmid: 19461022
references.citation: Stroke. 2010 May;41(5):885-90
references.pmid: 20224056
references.citation: CNS Neurosci Ther. 2013 Jan;19(1):43-7
references.pmid: 23206165
references.citation: Stroke. 2013 Mar;44(3):870-947
references.pmid: 23370205
references.citation: Hypertension. 2014 Jan;63(1):54-60
references.pmid: 24126175
references.citation: J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):855-60
references.pmid: 23954609
references.citation: Lancet. 2015 Feb 14;385(9968):617-28
references.pmid: 25465108